Patent intelligence · US
US 8362060
Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
Patent details — US 8362060
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 29, 2013
- Expiration
- Jan 24, 2033
- Applicant
- Theravance, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K31/4164, A61K45/06, A61P
Quick answer
US 8362060 (Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid) is held by Theravance, Inc.. Status: granted. Granted Jan 29, 2013. Expires Jan 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/4164, A61K45/06, A61P, A61P43/00, A61P5/42
More from Theravance, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8362060?
US 8362060 (Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid) is held by Theravance, Inc.. Status: granted. Granted Jan 29, 2013. Expires Jan 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8362060?
Theravance, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8362060 expire?
Our index shows an expiration date of Jan 24, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.